Q3 EPS Estimates for Urogen Pharma Lifted by HC Wainwright

Urogen Pharma (NASDAQ:URGN) – Research analysts at HC Wainwright upped their Q3 2027 earnings per share estimates for Urogen Pharma in a research report issued to clients and investors on Monday, May 11th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of $0.28 for the quarter, up from their previous forecast of $0.27. HC Wainwright currently has a “Buy” rating and a $45.00 target price on the stock. The consensus estimate for Urogen Pharma’s current full-year earnings is ($1.13) per share. HC Wainwright also issued estimates for Urogen Pharma’s Q4 2027 earnings at $0.49 EPS and FY2027 earnings at $0.50 EPS.

URGN has been the subject of a number of other research reports. Jefferies Financial Group upgraded Urogen Pharma to a “strong-buy” rating in a research report on Friday, April 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of Urogen Pharma in a research note on Monday, April 20th. D. Boral Capital restated a “buy” rating and set a $33.00 price target on shares of Urogen Pharma in a report on Tuesday, March 31st. Oppenheimer upped their price objective on Urogen Pharma from $34.00 to $40.00 and gave the stock an “outperform” rating in a report on Thursday, May 7th. Finally, LADENBURG THALM/SH SH began coverage on Urogen Pharma in a research report on Monday. They set a “buy” rating and a $43.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $36.67.

Urogen Pharma Stock Performance

Shares of NASDAQ URGN opened at $31.33 on Tuesday. The company has a market cap of $1.53 billion, a P/E ratio of -11.39 and a beta of 1.58. Urogen Pharma has a 52-week low of $3.42 and a 52-week high of $32.37. The firm’s fifty day moving average is $20.97 and its two-hundred day moving average is $21.74.

Urogen Pharma (NASDAQ:URGN) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.01. The company had revenue of $50.96 million for the quarter, compared to analysts’ expectations of $44.83 million.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in URGN. Mirae Asset Global Investments Co. Ltd. raised its position in Urogen Pharma by 27.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company’s stock valued at $53,000 after purchasing an additional 486 shares during the period. CWM LLC boosted its holdings in shares of Urogen Pharma by 18.0% in the 3rd quarter. CWM LLC now owns 4,271 shares of the company’s stock worth $85,000 after purchasing an additional 650 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Urogen Pharma by 7.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company’s stock valued at $258,000 after purchasing an additional 1,653 shares during the last quarter. Main Street Financial Solutions LLC raised its holdings in Urogen Pharma by 8.2% during the 2nd quarter. Main Street Financial Solutions LLC now owns 25,968 shares of the company’s stock valued at $356,000 after buying an additional 1,968 shares during the period. Finally, Barclays PLC lifted its position in Urogen Pharma by 3.8% in the fourth quarter. Barclays PLC now owns 57,744 shares of the company’s stock worth $1,352,000 after buying an additional 2,125 shares during the last quarter. Hedge funds and other institutional investors own 91.29% of the company’s stock.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.